QELBREE is an extended-release viloxazine medicine for ADHD. Its capsule instructions, interaction restrictions and boxed warning about suicidal thoughts and behaviors are central to understanding the product.
The approved uses and formulations described here follow US prescribing information. They may differ in other countries.
| Medicine detail | Details |
|---|---|
| Active ingredient(s) | viloxazine hydrochloride (strengths expressed as viloxazine) |
| Medicine class | Selective norepinephrine reuptake inhibitor |
| Forms and strengths | Extended-release oral capsules: 100, 150 and 200 mg |
The ADHD role described in the label
The US label covers attention-deficit/hyperactivity disorder in adults and children aged 6 years and older. Viloxazine is a selective norepinephrine reuptake inhibitor. A diagnosis and follow-up plan are needed; the medicine name alone does not determine whether this treatment is appropriate.
Source: [1]
An extended-release capsule with specific handling
The capsules contain 100, 150 or 200 mg of viloxazine and are used once daily under prescribed directions. They may be swallowed whole or opened onto the foods specified in the label. Do not crush or chew the contents. Ask the pharmacist to demonstrate the approved method if swallowing is difficult.
Source: [1]
Mood changes need close attention
QELBREE carries a boxed warning about suicidal thoughts and behaviors. Patients and caregivers should report new or worsening mood or behavioral symptoms promptly, especially around treatment initiation and dose changes. Immediate danger requires emergency help. Screening for bipolar disorder is part of the pretreatment assessment.
Source: [1]
Pulse, alertness and interactions
Blood pressure and heart rate should be assessed before treatment, after dose increases and periodically. Sleepiness and fatigue can affect driving. MAO inhibitors and certain sensitive CYP1A2 substrates are contraindicated combinations. Kidney impairment can also change the prescribed regimen, so a pharmacist should check the complete medicine list.
Source: [1]
Checking the exact prescription
The extended-release wording belongs on the prescription and pack. Capsule strength is separate from the total prescribed daily amount. Keep the package leaflet available for administration and missed-dose questions. A comparison of ADHD products can clarify identities, but does not supply an individual switching schedule.
The QELBREE and Strattera comparison brings the two product identities and selected label facts together for further reading.
Source: [1]
Questions and answers
Can QELBREE capsules be crushed?
No. The label permits specific sprinkle methods, but the capsule contents must not be crushed or chewed.
Why check blood pressure during QELBREE treatment?
Viloxazine can increase blood pressure and heart rate; the label calls for baseline and continuing checks.
Is QELBREE labeled for children younger than 6?
The cited US indication begins at age 6. It should not be extended to younger children from this reference.
Related reading
Sources
Sources checked 27 October 2026. This information does not replace advice from your healthcare professional. For complete warnings and instructions, read the product information and consult the prescribing team.
Reviewed by: Mattias Hagman, PhD
About the reviewer:
Dr Mattias Hagman (PhD, University of Sydney) has an academic background and experience working with healthcare-related content and regulated industries. He has lecturing experience at international universities, including Stockholm University and the University of Malta.
Last reviewed: October 2026